All In Biotech

Drug Trial Radar · NCT07652762

IN10018 in Combination With Dalpiciclib for Progressive Meningiomas

An Open-Label Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Efficacy of IN10018 in Combination With Dalpiciclib in Participants With Progressive Meningiomas

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Aug 2028

Study completion Aug 2029

Sponsor

Lead sponsor
Capital Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment. Participants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 and dalpiciclib will each be taken once daily for 21 days, followed by 7 days off in each 28-day cycle. Treatment may continue until the tumor progresses, unacceptable side effects occur, or another reason for stopping treatment applies. The study includes a dose-confirmation phase and a dose-expansion phase. The main goals are to evaluate side effects and determine a recommended dose of the combination for further study. Researchers will also assess whether the treatment can shrink tumors or delay tumor growth, measure how the drugs are processed in the body, and explore tumor and blood biomarkers that may be associated with treatment response.

Conditions

  • Meningioma
  • CDK4/6 Inhibitor

Interventions

  • IfebemtinibDrug

    Ifebemtinib (IN10018) is an investigational oral focal adhesion kinase inhibitor. It will be administered at a starting dose of 100 mg once daily on Days 1 through 21 of each 28-day treatment cycle, followed by 7 days without IN10018. If the starting dose is not tolerated, the dose may be reduced to 50 mg once daily. Ifebemtinib will be administered in combination with dalpiciclib until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined discontinuation criterion.

  • DalpiciclibDrug

    Dalpiciclib is an oral, selective cyclin-dependent kinase 4 and 6 inhibitor. It will be administered at a starting dose of 125 mg once daily on Days 1 through 21 of each 28-day treatment cycle, followed by 7 days without dalpiciclib. If the starting dose is not tolerated, the dose may be reduced to 100 mg once daily. Dalpiciclib will be administered in combination with ifebemtinib until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined discontinuation criterion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: Dose-limiting toxicities will be assessed at the end of Cycle 1 (each cycle is 28 days).
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: Adverse events will be assessed from the first dose through 30 days after the last dose of study treatment, up to approximately 24 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sanbo Brain Hospital, Capital Medical University

    Beijing, China · Not yet recruiting

  • Beijing Sanbo Brain Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.